What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Anti-BDCA2 human monoclonal antibody, concentrate for solution for infusion intravenously”In the company’s words, NCT07136389 on ClinicalTrials.gov
- Tested for
- Systemic Lupus Erthematosus
- Main trialPhase 1
- “The goal of this clinical trial to investigate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of BCD-256 alone and in combination with anti-CD20 therapy (divozilimab) as second- or later-line therapy in subjects with skin lesions due to mild to moderate systemic lupus erythematosus. The study consists of the first stage (cohorts 1-5) and the second stage (cohorts A - D).”In the company’s words, NCT07136389 on ClinicalTrials.gov
- Other names
- Anti-BDCA2
Other drugs for Systemic Lupus Erthematosus
- CenerimodViatris Innovation GmbH · Phase 3
- IanalumabNovartis Pharmaceuticals · Phase 3
- UpadacitinibAbbVie · Phase 3
- QL1074Qilu Pharmaceutical · Phase 3
- Dapirolizumab pegolUCB Biopharma SRL · Phase 3
- Mycophenolate MofetilRoche · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 1 Jan 2026 | Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026